MedTrace Logo

Precision Medicine for Combined Hepatocellular-Cholangiocarcinoma

NCT06146127 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2023-11-24

No results posted yet for this study

Summary

Our project is a large-scale characterisation of cHCC-CCA will allow us to determine which subsets harbor actionable gene alterations. We will also aim to improve diagnosis of this tumor type by the use of immunohistochemical biomarkers and the development of deep-learning based models able to help cHCC-CCA diagnosis. This will represent an important step towards precision medicine for the patients with this highly aggressive malignancy.

Conditions

Interventions

OTHER

phenotyping

Large scale molecular phenotyping

Sponsors & Collaborators

  • Inserm U955

    lead OTHER

Principal Investigators

  • Julien Calderaro · Inserm/APHP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-01-15
Primary Completion
2023-01-15
Completion
2025-01-30

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06146127 on ClinicalTrials.gov